RxDoctor Payments Data

Loc Bui, MD

Internal Medicine · Westminster, CANPI 1023081387

Payments from drug & device makers

$3,012in general payments, 2019–2025

Across 33 payments — averaging $91.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$869
  • Bayer$394
  • Boehringer Ingelheim$237
  • Amarin Pharma, Inc.$210
  • Novo Nordisk$163
  • Sanofi Pasteur Inc.$127
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$3,012100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,012 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$128,430
Medicare patients
87
Services billed
1,287

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VemlidyTenofovir Alafenamide35$51,611
JardianceEmpagliflozin72$50,545
TradjentaLinagliptin62$44,223
TrulicityDulaglutide27$36,006
LinzessLinaclotide35$20,254
GemtesaVibegron33$17,544
EliquisApixaban15$17,218
ZenpepLipase/Protease/Amylase27$10,085
Celecoxib208$2,436
Atorvastatin Calcium354$2,173
Levothyroxine Sodium82$2,069
Febuxostat24$1,838
Megestrol Acetate29$1,751
Losartan Potassium278$1,618
Tamsulosin Hcl129$1,292

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$237$94,768134 claims
GileadVemlidy$869$51,61135 claims
Lilly USA, LLCTrulicity$99$36,00627 claims
AbbVieLinzess$110$20,25435 claims
Sumitomo Pharma America, Inc.Gemtesa$109$17,54433 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Westminster

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →